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CASE REPORT
Typical graves’ ophthalmopathy in primary hypothyroidism
Zareen Kiran, Owais Rashid, Najmul Islam

Abstract
Graves ophthalmopathy (GO) usually occurs in a close
temporal relationship with hyperthyroidism. It is rare in
patients with normal thyroid function (euthyroid GO) and
in patients with hypothyroid forms of thyroid
autoimmune diseases (hypothyroid GO). We report a 52years old man presenting in our endocrine clinic with
diagnosed primary hypothyroidism 3 months back during
evaluation for glaucoma. He was later referred by an
ophthalmologist to exclude Grave's eye disease, where he
had presented with chief complaints of bilateral
prominent eyes. On examination there was only bilateral
exophthalmos with marked chemosis. Magnetic
resonance imaging (MRI) of the orbits showed typical
findings of GO. Grave's ophthalmopathy is a rare
condition to come across in patients with primary
hypothyroidism, and is being first time reported from
Pakistan. Patients with hypothyroidism and Graves
ophthalmopathy can be successfully treated with steroids
in a similar manner as in patients with GO associated with
hyperthyroidism.
Keywords: Thyroid associated orbitopathy, Graves
ophthalmopathy, Hypothyroidism.

Introduction
The presence of Graves' eye disease is well studied in
association with thyroid hormone dysfunction, most
commonly hyperthyroidism. It is an important
manifestation in patients with Graves' disease in
euthyroid, hyperthyroid or even in hypothyroid state.
However, occurrence of typical Graves' ophthalmopathy
in patients known to have primary hypothyroidism is very
rare. A recent review study from Japan has described an
incidence of Graves' ophthalmopathy in patients who
have never been hyperthyroid (i.e. euthyroid and
hypothyroid Graves' disease) between 2.5 to 34.3%.1
Hypothyroid Graves' ophthalmopathy generally has
typical manifestation of Graves' eye disease as in patients
with thyrotoxicosis. It is characterized by inflammatory
infiltration of the orbital contents. Patients have been
found to have thyroid stimulating hormone (TSH)
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receptor antibodies positive in their serum with euthyroid
or hypothyroid Graves' ophthalmopathy but does not
explain pathogenic correlation with underlying thyroid
dysfunction as they are negative or weakly positive in
euthyroid Grave's disease.2,3

Case Report
A 52 years old man presented for the first time in our
endocrine clinic in March 2015, with complaints of
constipation and swelling of the feet for 3 months. He was
diagnosed to have primary hypothyroidism 3 months back
during evaluation and treatment for glaucoma. In his past
history he had Idiopathic transverse myelitis in January
2014, for which he was treated with steroids for 4 months
in tapering regime. He did not report any history of
arthritis, however he had impaired fasting glucose and was
on dietary and lifestyle modification. The patient had
never smoked. He was on levothyroxine 100 microgram
daily. He also had a family history of hypothyroidism in his
daughter. On examination, he was vitally stable, with
insignificant findings on general physical and systemic
examination. Laboratory investigations showed a thyroid
stimulating hormone level (TSH) of 7.5 uIU/ml (NR: 0.4-4)
and free T 4 (FT4) level of 1.24 ng/dl (NR: 0.89-1.76). His
dose of levothyroxine was adjusted and he was asked to
follow up with thyroid antibodies. On next visit, three
months later, he was clinically euthyroid. Laboratory
investigations showed TSH level of 1.41 uIU/ml, FT4 level
was 1.11ng/dl and his anti-thyroid peroxidase (anti-TPO)
was 958 IU/ml (NR: <35) and anti-thyroglobulin (anti-TG)
was 60.3 IU/ml (NR: <40). He then presented again after 4
months, this time he was referred by an ophthalmologist
to exclude Grave's eye disease, where he had presented
with chief complaints of bilateral prominent eyes. On

Figure-1: T1 weighted image in axial section showing enlarged medial recti (arrows)
bilaterally.
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Box-1: Grave's Eye signs present in our patient.
Bilateral exophthalmos
Bilateral proptosis
Bilateral chemosis (erythematous conjunctiva & excessive lacrimation)
Table-1: Werner's NOSPECS Classification of Grave's ophthalmopathy.
Class

Clinical
Features

Clinical features
present in our patient

Class 0
Class I

No symptoms or signs
Only signs, no symptoms
(e.g. lid retraction, stare, lid lag)
Soft tissue involvement
Proptosis
Extraocular muscle involvement
Corneal involvement
Sight loss (optic nerve involvement)

-

Class II
Class III
Class IV
Class V
Class VI

Present
Present
Present
-

examination there was bilateral exophthalmos and
proptosis with marked chemosis, but without any diplopia
(Box-1). On neck examination, there was no goiter or bruit.
He had no tremors and there was no pretibial myxedema.
He was advised to get MRI of the orbits to assess the cause
of exophthalmos. MRI of the orbits showed enlargement of
extraocular muscles, particularly the medial and inferior
rectus muscles which are typical findings of Grave's
ophthalmopathy. There was no space occupying lesion
identified on MRI as the cause of exophthalmos. He was
started on tapering regime of prednisone 40mg per OS
daily for 2 weeks, then 20mg daily for 2 weeks, then 10mg
daily for 1 week and finally 5mg daily for 1 week, along
with Omeprazole 40 mg per OS daily. On follow up he had
recovered well with resolution of chemosis and normal
vision. Informed consent was taken from the patient's son
for reporting this rare presentation.

dynamic active progressive phase characterized by marked
inflammatory infiltrate with lymphocytes in the orbital
tissues involving extraocular muscles and fat, followed by a
static phase in which inflammation subsides and fibroblasts
come into play resulting in fibrosis which may cause
permanent disfigurement of the eyes and diplopia.6 How
does this pathophysiology correlates with thyroid hormone
status in individuals is not clearly evident. Presence of high
titers of TSH receptor antibodies in patients with Grave's
hyperthyroidism have shown to explain the autoimmune
basis for ophthalmopathy, due to the presence of TSH
receptors in orbital fibroblasts, but these antibodies are not
found to be elevated in patients with hypothyroidism.2,7
Patients with Grave's disease can undergo a phase of
hypothyroidism in the natural history of their disease
process, but our patient had never been diagnosed with
hyperthyroidism in the past, nor was there any history of
radioactive iodine ablation. Moreover, we could neither label
nor exclude this patient to have Grave's eye disease as we did
not have thyroid stimulating immunoglobulins/receptor
antibodies (TSI/TRAb) assay available in our facility to
confirm the diagnosis. The anti-TPO and anti-TG antibodies
done in this patient, could in fact, favour the diagnosis of
Hashimoto's thyroiditis. Hashimoto's thyroiditis usually
comprises of an initial thyrotoxic phase followed by a
transient hypothyroidphase with only around 5% patients
developing permanent hypothyroidism. However, our
patient does not describe any stigmata of hyperthyroidism
even in the past to account for the Hashitoxicosis phase of
Hashimoto's thyroiditis.

Ophthalmopathy associated with primary hypothyroidism
is a rare phenomenon, occurring in 7.5% of patients with
known primary hypothyroidism as reported in one of the
clinical study from Iran.4 It was first reported by Wyse et al
in 1968.5 Since then many case reports and some clinical
studies from different parts of the world are being
reported and epidemiological data shows that it is still an
unusual entity in patients with known hypothyroidism.
Several studies have shown that there are demographic
differences with Asians having less severe manifestation
and Caucasians being at higher risk.1

Patients with Hashimoto's thyroiditis usually test negative for
TSH receptor antibodies but still have typical Grave's eye
disease, elucidating the presence of other eye muscle
antigens as the cause of autoimmune basis for the disease
process.8 Our patient did have typical findings of Grave's
ophthalmopathy on imaging9,10 (Figure-1). The American
Thyroid Association has proposed a more objective method
for determining the eye changes of Graves' disease and
overall assessment of severity through a scoring system,
where Clinical Activity Score (CAS) of > 3 is considered to have
active inflammation.11,12 This results in more reliable
assessment of ophthalmopathy and requiring orbital
imaging early in the course of disease, hence starting early
treatment.13 Thyroid associated ophthalmopathy is also
classified clinically with the well-remembered Werner'
NOSPECS classification corresponding Class 0 to VI14 (Table-1).
The clinical activity score of our patient was 3, as there was
marked chemosis, redness of the eyes and swelling of eyelids.

The underlying pathogenesis, though not very clear, is
same as in patients with hyperthyroid Grave's
ophthalmopathy. The natural history comprises of an initial

Treatment of Grave's ophthalmopathy associated with
hypothyroidism is not well defined in the literature. However,
it is aimed at immunomodulation similar to ophthalmopathy

Discussion
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in Grave's disease. Patients with hypothyroid
ophthalmopathy can continue on thyroid replacement with
levothyroxine with simultaneous treatment of Grave's
ophthalmopathy.15 Glucocorticoids in high dose remain the
mainstay of initial therapy with prolonged tapering regimes
and often requiring longer duration of maintenance therapy
before completely withdrawing. The choice of route for
steroid treatment has been studied in four clinical trials so far
and the response to intravenous route is 77% versus 51% in
one of them.16-19 Orbital radiotherapy has been thought to
be most effective in reducing inflammation with little or no
change in proptosis or muscle function, with an overall 60%
response rate.20 Orbital decompression surgeries are usually
performed when there is sight threatening optic nerve
compression or a need of cosmetic correction for strabismus
and diplopia. Newer immunomodulating agents like
rituximab and etanercept are underway and several
randomized trials are required to bring more novel
treatment options for improving the quality of life of patients
with thyroid associated ophthalmopathy.7

Conclusions
In conclusion, ophthalmopathy associated with
hypothyroidism is very rare and never been reported from
Pakistan. Our patient had typical findings of Graves
ophthalmopathy supported by clinical and imaging
criteria. We did not have the facility of TSH receptor
antibodies level to support the underlying Grave's
autoimmune phenomenon and our patient was diagnosed
as primary hypothyroidism in first place. However, the
classic presentation of Grave's ophthalmopathy should
prompt evaluation regardless of thyroid status, as timely
treatment is important to save blindness and morbidity.
Disclaimer: The abstract has been published in the
Abstract Book of Pakistan Endocrine Society Annual
Conference held on 18-20th December 2015.
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